Overview

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

Status:
Not yet recruiting
Trial end date:
2024-01-11
Target enrollment:
Participant gender:
Summary
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene